Written and peer-reviewed by physicians—but use at your own risk. Read our disclaimer.

banner image


Trusted medical answers—in seconds.

Get access to 1,000+ medical articles with instant search
and clinical tools.

Try free for 5 days

Hepatitis B

Last updated: July 17, 2020


Hepatitis B virus (HBV) is a common viral infection worldwide and can be transmitted sexually, parenterally, or perinatally. After an incubation period of 1–6 months, most patients present with an asymptomatic or mild inflammation of the liver, which usually resolves spontaneously within a few weeks or months. However, 5% of all adult patients and 90% of infants born to a hepatitis B-positive mother develop chronic hepatitis. Chronically infected individuals may be either asymptomatic carriers or exhibit ongoing hepatic inflammation with an increased risk of liver cirrhosis and hepatocellular carcinoma. Serologic testing, which is decisive for diagnosing HBV, initially involves measurement of HBs antigen. An increase in serum anti‑HBs (also known as seroconversion) is a sign of recovery or successful immunization. Chronic hepatitis is indicated by persistently elevated HBs antigen levels, as well as high HBV DNA and transaminase levels in cases of persistent liver inflammation. Treatment of acute hepatitis B consists of supportive measures. In the case of fulminant hepatitis, liver transplantation may be necessary. For chronic hepatitis B, pegylated interferon alpha and nucleoside/nucleotide analogs (e.g., tenofovir) are used to reduce viral replication and infectivity. Prophylactic immunization with a recombinant vaccine is recommended for all age groups. Other preventative measures include post-exposure prophylaxis for newborns of hepatitis B-positive mothers and unvaccinated individuals with recent exposure to those who are hepatitis B-positive.


  • More than 248 million people worldwide are chronically infected.
  • ∼ 600,000 deaths annually from HBV-related liver disease
  • High prevalence in Asia, Africa, and the Amazon basin
  • United States


Epidemiological data refers to the US, unless otherwise specified.




The frequency and patterns of transmission vary worldwide.

  1. Sexual
  2. Parenteral
    • Needlestick injury
    • Contaminated instruments and shared needles
    • Contaminated blood products
  3. Perinatal

High-risk groups for HBV infection

Individuals whose medical history indicates a high risk for HBV infection should be tested!



Acute infection

Hepatocytes infected by the hepatitis B virus express viral peptides on their surfaces lymphocytes recognize HBV-derived peptides and become activated (CD8+ cytotoxic T cells) → lymphocytes attack liver cells (cellular immune response) → hepatic inflammation with destruction of hepatocytes

Chronic infection

If clearance of the virus fails


Clinical features

Incubation period

  • 1–6 months

Acute infection

Acute HBV infections are defined as infections that were acquired in the past 6 months.

Recovery rates in adults are very good, with less than 5% of cases progressing to chronic infections. In contrast, the risk of developing chronic hepatitis is considerably higher in infants infected perinatally (90%) and young children (20–50%)!

Chronic infection

Chronic HBV infections are defined as infections persisting for more than 6 months with detection of HBsAg and possibly symptoms of liver damage.



Diagnostically relevant virus antigens, DNA, and antibodies

HBV antigen/DNA Description Corresponding antibodies
  • Hepatitis B surface antigen
  • Protein on the surface of HBV; first evidence of infection
  • Anti-HBs
    • Indicates immunity to HBV due to vaccination or resolved infection
    • Usually appears 1–3 months after infection.
  • Hepatitis B core antigen
  • Anti‑HBc
    • Anti-HBC IgM indicates recent infection with HBV (≤ 6 months)
    • Anti-HBc IgG indicates resolved or chronic infections
  • Hepatitis B envelope antigen
  • Protein secreted by the virus that indicates viral replication and infectivity
  • Anti‑HBe
    • Indicates long-term clearance of HBV

Hepatitis B serology

HBsAg Anti-HBs


Anti-HBe Anti-HBc HBV DNA Transaminases
Acute infection IgM ∅–↑ (ALT > AST)

Window period

∅–↑ IgM first, then IgG ∅–↑ (ALT > AST)
Resolved prior infection IgG

Virus persistence (chronic infection)

Active chronic infection


HBV DNA > 2000 IU/mL

Normal or ↑

Inactive chronic infection

IgG HBV DNA ≤ 2000 IU/mL Normal

Additional tests

Seroconversion of HBsAg to anti‑HBs indicates immune clearance of HBV!

HBeAg indicates Infectivity due to viral Existence(/persistence)!


Acute viral hepatitis

Chronic viral hepatitis

Ground glass hepatocytes are only present in HBV, while piecemeal necrosis, fibrous septa, and periportal infiltrates also occur in other types of chronic hepatitis!




Differential diagnoses

Differential diagnosis of viral hepatitis
Pathogen Viral family Transmission route Incubation period (days) Symptoms/Signs Serological diagnosis Treatment Prevention Complications
Hepatitis A virus (HAV)
  • Fecal-oral
  • 15–50
  • Supportive
  • Full recovery within ∼ 3 months
  • Does not become chronic
Hepatitis B virus (HBV)
  • 30–180
  • Safe sex; screening of blood products; use of sterile instruments and needles
  • HBV vaccination, post-exposure prophylaxis
Hepatitis C virus (HCV)
  • 14–180
  • Use of sterile instruments and needles; safe sex
  • No vaccination for HCV available
Hepatitis D virus (HDV)
  • Peginterferon-α
  • Prevention of HBV infection (see “Prevention” below)

Hepatitis E virus (HEV)

  • Fecal-oral
  • 15–64
  • Acute: supportive

Hepatitis viruses A and E usually only cause AcutE hepatitis!

The differential diagnoses listed here are not exhaustive.


Acute hepatitis B

Chronic hepatitis B



Hepatitis D virus infection

Acute liver failure

Long-term complications of hepatitis B


We list the most important complications. The selection is not exhaustive.



Special patient groups

Perinatal hepatitis B

Whereas maternal hepatitis B; infections rarely cause fetal complications during pregnancy, the risk of perinatal transmission is high, especially if the maternal viral load is increased. If an infant becomes infected, the risk of developing chronic hepatitis is 90%.

Interferon therapy is contraindicated during pregnancy!


  1. Lok ASF. Hepatitis B Virus: Overview of Management. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. http://www.uptodate.com/contents/hepatitis-b-virus-overview-of-management.Last updated: February 15, 2017. Accessed: March 25, 2017.
  2. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015; 386 (10003): p.1546–1555. doi: 10.1016/S0140-6736(15)61412-X . | Open in Read by QxMD
  3. Epidemiology and Prevention of Vaccine-Preventable Diseases - Hepatitis B.
  4. Viral Hepatitis - Hepatitis B FAQs for the Public. https://www.cdc.gov/hepatitis/hbv/bfaq.htm. Updated: March 23, 2016. Accessed: March 25, 2017.
  5. Kasper DL, Fauci AS, Hauser SL, Longo DL, Lameson JL, Loscalzo J. Harrison's Principles of Internal Medicine. McGraw-Hill Education ; 2015
  6. Teo EK, SF Lok ASF. Epidemiology, Transmission, and Prevention of Hepatitis B Virus Infection. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. https://www.uptodate.com/contents/epidemiology-transmission-and-prevention-of-hepatitis-b-virus-infection.Last updated: October 31, 2016. Accessed: March 25, 2017.
  7. Hepatitis B. http://www.who.int/mediacentre/factsheets/fs204/en/. Updated: July 1, 2016. Accessed: March 25, 2017.
  8. Exposure to Blood - What Healthcare Personnel Need to Know.
  9. Swetha Samji N. Viral Hepatitis. In: Anand BS, Viral Hepatitis. New York, NY: WebMD. http://emedicine.medscape.com/article/775507. Updated: December 16, 2014. Accessed: March 25, 2017.
  10. Pyrsopoulos NT. Hepatitis B. In: Anand BS, Hepatitis B. New York, NY: WebMD. http://emedicine.medscape.com/article/177632. Updated: October 26, 2016. Accessed: March 25, 2017.
  11. Beck J, Nassal M. Hepatitis B virus replication. World J Gastroenterol. 2007; 13 (1): p.48-64.
  12. Hai H, Tamori A, Kawada N. Role of hepatitis B virus DNA integration in human hepatocarcinogenesis. World J Gastroenterol. 2014; 20 (20): p.6236-43. doi: 10.3748/wjg.v20.i20.6236 . | Open in Read by QxMD
  13. Wener MH. Serum Sickness and Serum Sickness-Like Reactions. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. https://www.uptodate.com/contents/serum-sickness-and-serum-sickness-like-reactions.Last updated: October 19, 2015. Accessed: February 16, 2017.
  14. Yung A, Spelman D, Street A, McCormack J, Sorrell T, Johnson P. Infectious Diseases: A Clinical Approach. IP Communications ; 2010
  15. Lok ASF. Clinical Manifestations and Natural History of Hepatitis B Virus Infection. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. https://www.uptodate.com/contents/clinical-manifestations-and-natural-history-of-hepatitis-b-virus-infection.Last updated: May 4, 2015. Accessed: March 25, 2017.
  16. Sharma SK, Saini N, Chwla Y. Hepatitis B virus: inactive carriers. Virol J. 2005; 2 : p.82. doi: 10.1186/1743-422X-2-82 . | Open in Read by QxMD
  17. Le T, Bhushan V, Chen V, King M. First Aid for the USMLE Step 2 CK. McGraw-Hill Education ; 2015
  18. Tran TT. Immune tolerant hepatitis B: a clinical dilemma. Gastroenterol Hepatol. 2011; 7 (8): p.511-516.
  19. Guidelines for treatment of chronic hepatitis B. https://www.aasld.org/sites/default/files/2019-06/HBVGuidance_Terrault_et_al-2018-Hepatology.pdf. Updated: November 13, 2015. Accessed: March 25, 2017.
  20. Kurtz AB, Rubin CS, Cooper HS, et al. Ultrasound findings in hepatitis. Radiology. 1980; 136 (3): p.717-723. doi: 10.1148/radiology.136.3.7403553 . | Open in Read by QxMD
  21. Lok ASF. Hepatitis B Virus: Screening and Diagnosis. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. https://www.uptodate.com/contents/hepatitis-b-virus-screening-and-diagnosis.Last updated: January 22, 2018. Accessed: April 6, 2018.
  22. Rubin E, Reisner HM. Essentials of Rubin's Pathology. Lippincott Williams & Wilkins ; 2009
  23. Ferrell L. Liver pathology: cirrhosis, hepatitis, and primary liver tumors: Update and diagnostic problems. Mod Pathol. 2000; 13 (6): p.679-704. doi: 10.1038/modpathol.3880119 . | Open in Read by QxMD
  24. Ju C, Tacke F. Hepatic macrophages in homeostasis and liver diseases: from pathogenesis to novel therapeutic strategies. Cell Mol Immunol. 2016; 13 (3): p.316-327. doi: 10.1038/cmi.2015.104 . | Open in Read by QxMD
  25. Cohen C. "Ground-glass" hepatocytes. S Afr Med J. 1975; 49 (34): p.1401-1403.
  26. Liver and Intrahepatic Bile Ducts - Nontumor - Hepatitis (Acute and Chronic) - Chronic Hepatitis - General. http://www.pathologyoutlines.com/topic/liverchronichepgeneral.html. Updated: October 31, 2017. Accessed: April 6, 2018.
  27. Agabegi SS, Agabegi ED. Step-Up To Medicine. Wolters Kluwer Health ; 2015
  28. Jenkins B, McInnis M, Lewis C. Step-Up to USMLE Step 2 CK. Lippincott Williams & Wilkins ; 2015
  29. Kumar V, Abbas AK, Aster JC. Robbins & Cotran Pathologic Basis of Disease. Elsevier Saunders ; 2015
  30. Remy P. Hepatitis E. In: Anand BS, Hepatitis E. New York, NY: WebMD. http://emedicine.medscape.com/article/178140. Updated: September 27, 2016. Accessed: March 24, 2017.
  31. Hepatitis A and the Vaccine (Shot) to Prevent It. https://www.cdc.gov/vaccines/parents/diseases/child/hepa.html. Updated: November 10, 2014. Accessed: March 25, 2017.
  32. Hepatitis D Infection Fact Sheet. http://www.health.state.mn.us/divs/idepc/diseases/hepatitis/hepdfact.html. Updated: March 25, 2017. Accessed: March 25, 2017.
  33. Dhawan VK. Hepatitis C. In: Anand BS, Hepatitis C. New York, NY: WebMD. http://emedicine.medscape.com/article/177792. Updated: March 28, 2016. Accessed: March 27, 2017.
  34. Lok ASF. Standard and Pegylated Interferon for Chronic Hepatitis B Virus Infection. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. https://www.uptodate.com/contents/standard-and-pegylated-interferon-for-chronic-hepatitis-b-virus-infection.Last updated: November 28, 2016. Accessed: March 25, 2017.
  35. Sabatine MS. Pocket Medicine: The Massachusetts General Hospital Handbook of Internal Medicine. Lippincott Williams & Wilkins ; 2013
  36. Review of Pathology of the Liver: Viral Hepatitis D.
  37. Goldberg E, Chopra S. Acute liver failure in adults: Management and prognosis. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. https://www.uptodate.com/contents/acute-liver-failure-in-adults-management-and-prognosis.Last updated: April 8, 2016. Accessed: March 25, 2017.
  38. Hepatitis D. http://www.who.int/mediacentre/factsheets/hepatitis-d/en/. Updated: July 1, 2017. Accessed: April 6, 2018.
  39. Xie Y. Hepatitis B virus-associated hepatocellular carcinoma. Springer Singapore ; 2017 : p. 11-21
  40. 2015 Sexually Transmitted Diseases Treatment Guidelines: Viral Hepatitis. https://www.cdc.gov/std/tg2015/hepatitis.htm. Updated: June 4, 2015. Accessed: March 25, 2017.
  41. Lexicomp Inc.. Hepatitis B Vaccine: Drug Information. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. https://www.uptodate.com/contents/hepatitis-b-vaccine-drug-information.Last updated: September 27, 2017. Accessed: September 27, 2017.
  42. Lee H, Lok ASF. Hepatitis B and pregnancy. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. http://www.uptodate.com/contents/hepatitis-b-and-pregnancy.Last updated: February 4, 2017. Accessed: March 25, 2017.
  43. Herold G. Internal Medicine. Herold G ; 2014
  44. Hepatitis E FAQs for Health Professionals. https://www.cdc.gov/hepatitis/hev/hevfaq.htm. Updated: May 31, 2015. Accessed: March 24, 2017.
  45. Daniels D, Grytdal S, Wasley A, Centers for Disease Control and Prevention (CDC).. Surveillance for acute viral hepatitis - United States, 2007.. Morbidity and mortality weekly report. Surveillance summaries (Washington, D.C. : 2002). 2009; 58 (3): p.1-27.
  46. Köck J, Schlicht HJ. Analysis of the earliest steps of hepadnavirus replication: genome repair after infectious entry into hepatocytes does not depend on viral polymerase activity.. J Virol. 1993; 67 (8): p.4867-74.
  47. Datta S, Chatterjee S, Veer V, Chakravarty R. Molecular Biology of the Hepatitis B Virus for Clinicians. Journal of Clinical and Experimental Hepatology. 2012; 2 (4): p.353-365. doi: 10.1016/j.jceh.2012.10.003 . | Open in Read by QxMD
  48. Urban S, Schulze A, Dandri M, Petersen J. The replication cycle of hepatitis B virus. J Hepatol. 2009; 52 (2): p.282-284. doi: 10.1016/j.jhep.2009.10.031 . | Open in Read by QxMD
  49. Franco E. Hepatitis A: Epidemiology and prevention in developing countries. World Journal of Hepatology. 2012; 4 (3): p.68. doi: 10.4254/wjh.v4.i3.68 . | Open in Read by QxMD
  50. MacLachlan JH, Cowie BC. Hepatitis B Virus Epidemiology. Cold Spring Harbor Perspectives in Medicine. 2015; 5 (5): p.a021410-a021410. doi: 10.1101/cshperspect.a021410 . | Open in Read by QxMD
  51. Mirazo S, Ramos N, Mainardi V, Arbiza J, Gerona S. Transmission, diagnosis, and management of hepatitis E: an update. Hepatic Medicine: Evidence and Research. 2014 : p.45. doi: 10.2147/hmer.s63417 . | Open in Read by QxMD
  52. Negro F. Hepatitis D Virus Coinfection and Superinfection. Cold Spring Harbor Perspectives in Medicine. 2014; 4 (11): p.a021550-a021550. doi: 10.1101/cshperspect.a021550 . | Open in Read by QxMD
  53. Kamar N, Izopet J, Dalton HR. Chronic Hepatitis E Virus Infection and Treatment. Journal of Clinical and Experimental Hepatology. 2014; 3 (2): p.134-140. doi: 10.1016/j.jceh.2013.05.003 . | Open in Read by QxMD
  54. Matheny SC, Kingery JE. Hepatitis A.. Am Fam Physician. 2012; 86 (11): p.1027-34; quiz 1010-2.
  55. Hepatitis B Questions and Answers for Health Professionals. https://www.cdc.gov/hepatitis/hbv/hbvfaq.htm#overview. Updated: March 16, 2020. Accessed: July 23, 2020.
  56. Epidemiological estimates of viral hepatitis. https://www.who.int/westernpacific/health-topics/hepatitis/regional-hepatitis-data. Updated: July 23, 2018. Accessed: July 23, 2020.
  57. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors. J Hepatol. 2008; 48 (2): p.335-352. doi: 10.1016/j.jhep.2007.11.011 . | Open in Read by QxMD
  58. Jafri S, Gordon SC. Epidemiology of Hepatitis C. Clinical Liver Disease. 2018; 12 (5): p.140-142. doi: 10.1002/cld.783 . | Open in Read by QxMD
  59. Farci P, Niro G. Clinical Features of Hepatitis D. Semin Liver Dis. 2012; 32 (03): p.228-236. doi: 10.1055/s-0032-1323628 . | Open in Read by QxMD
  60. Wedemeyer H, Pischke S, Manns MP. Pathogenesis and Treatment of Hepatitis E Virus Infection. Gastroenterology. 2012; 142 (6): p.1388-1397.e1. doi: 10.1053/j.gastro.2012.02.014 . | Open in Read by QxMD
  61. Choi M, Hofmann J, Köhler A, et al. Prevalence and Clinical Correlates of Chronic Hepatitis E Infection in German Renal Transplant Recipients With Elevated Liver Enzymes. Transplantation Direct. 2018; 4 (2): p.e341. doi: 10.1097/txd.0000000000000758 . | Open in Read by QxMD
  62. Guan R, Lui HF. Treatment of Hepatitis B in Decompensated Liver Cirrhosis. International Journal of Hepatology. 2011; 2011 : p.1-11. doi: 10.4061/2011/918017 . | Open in Read by QxMD
  63. Manka P, Verheyen J, Gerken G, Canbay A. Liver Failure due to Acute Viral Hepatitis (A-E). Visceral Medicine. 2016; 32 (2): p.80-85. doi: 10.1159/000444915 . | Open in Read by QxMD
  64. Schillie S, Vellozzi C, Reingold A, et al. Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices. MMWR. Recommendations and Reports. 2018; 67 (1): p.1-31. doi: 10.15585/mmwr.rr6701a1 . | Open in Read by QxMD
  65. Patel DM, Butler J, Feldman S, Graves GR, Rhodes PG. Immunogenicity of hepatitis B vaccine in healthy very low birth weight infants. J Pediatr. 1997; 131 (4): p.641-643. doi: 10.1016/s0022-3476(97)70078-7 . | Open in Read by QxMD
  66. Prevention Tips for Hepatitis B. https://www.hepb.org/prevention-and-diagnosis/prevention-tips/. . Accessed: July 27, 2020.
  67. Harris AM, Iqbal K, Schillie S, et al. Increases in Acute Hepatitis B Virus Infections — Kentucky, Tennessee, and West Virginia, 2006–2013. MMWR Morb Mortal Wkly Rep. 2016; 65 (3): p.47-50. doi: 10.15585/mmwr.mm6503a2 . | Open in Read by QxMD
  68. Hyun Kim B, Ray Kim W. Epidemiology of Hepatitis B Virus Infection in the United States. Clinical Liver Disease. 2018; 12 (1): p.1-4. doi: 10.1002/cld.732 . | Open in Read by QxMD
  69. Surveillance for Viral Hepatitis – United States, 2017. https://www.cdc.gov/hepatitis/statistics/2017surveillance/index.htm. Updated: November 14, 2019. Accessed: July 28, 2020.
  70. Balmasova IP. Immunopathogenesis of chronic hepatitis B. World Journal of Gastroenterology. 2014; 20 (39): p.14156. doi: 10.3748/wjg.v20.i39.14156 . | Open in Read by QxMD
  71. Burns GS, Thompson AJ. Viral Hepatitis B: Clinical and Epidemiological Characteristics. Cold Spring Harbor Perspectives in Medicine. 2014; 4 (12): p.a024935-a024935. doi: 10.1101/cshperspect.a024935 . | Open in Read by QxMD